Suppression of Akt-mTOR pathway - A novel component of oncogene induced DNA damage response barrier in breast tumorigenesis

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Bhardwaj, Anjana ^a   Rosen, Daniel ^a   Liu, Mei ^a   Liu, Yan ^a   Hao, Qiang ^a   Ganesan, Nivetha ^a   Etzel, Carol J ^a   Gullett, Ashley ^a   Albarracin, Constance T ^a   Bedrosian, Isabelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; DNA; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; AUTOPHAGY; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; BREAST DISEASE; CANCER INHIBITION; CANCER RISK; CANCER TISSUE; CONTROLLED STUDY; DNA DAMAGE; DNA DAMAGE RESPONSE; FEMALE; GENETIC PARAMETERS; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMORTALIZED CELL LINE; IN VITRO STUDY; INTRADUCTAL CARCINOMA; MCF10A CELL LINE; METABOLIC INHIBITION; MOLECULAR CLONING; ONCOGENE; PROLIFERATIVE BREAST DISEASE; SIGNAL TRANSDUCTION; BREAST TUMOR; CARCINOGENESIS; CELL PROLIFERATION; GENETICS; MAMMARY GLAND; METABOLISM; PATHOLOGY; RISK; TUMOR CELL LINE; TUMOR INVASION;

AUTOPHAGY; BREAST NEOPLASMS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN E; DNA DAMAGE; FEMALE; HUMANS; MAMMARY GLANDS, HUMAN; NEOPLASM INVASIVENESS; ONCOGENES; PROTO-ONCOGENE PROTEINS C-AKT; RISK; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84901045092     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097076     Document Type: Article

References (30)

1. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, et al. (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444: 638-642. (Pubitemid 44864443)
2. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, et al. (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907-913. (Pubitemid 40559004)
3. Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA damage model for cancer development. Science 319: 1352-1355. (Pubitemid 351354863)
4. Tort F, Bartkova J, Sehested M, Orntoft T, Lukas J, et al. (2006) Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis. Cancer Res 66: 10258-10263. (Pubitemid 44799741)
5. Meek DW (2009) Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9: 714-723.
6. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, et al. (1990) Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075-6086. (Pubitemid 20331424)
7. Russo J, Tait L, Russo IH (1991) Morphological expression of cell transformation induced by c-Ha-ras oncogene in human breast epithelial cells. J Cell Sci 99 (Pt 2): 453-463. (Pubitemid 21925032)
8. Miller FR, Soule HD, Tait L, Pauley RJ, Wolman SR, et al. (1993) Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst 85: 1725-1732. (Pubitemid 23320842)
9. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, et al. (2001) Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 65: 101-110. (Pubitemid 32193613)
10. Krajewska M, Smith LH, Rong J, Huang X, Hyer ML, et al. (2009) Image analysis algorithms for immunohistochemical assessment of cell death events and fibrosis in tissue sections. J Histochem Cytochem 57: 649-663.
11. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, et al. (2004) Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64: 3198-3208. (Pubitemid 38581423)
12. Fiebiger W, Olszewski U, Ulsperger E, Geissler K, Hamilton G (2011) In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines. Clin Transl Oncol 13: 43-49.
13. Santisteban M, Reynolds C, Barr Fritcher EG, Frost MH, Vierkant RA, et al. (2010) Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Res Treat 121: 431-437.
14. Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, et al. (2007) Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67: 7212-7222. (Pubitemid 47206549)
15. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870. (Pubitemid 40558993)
16. Bozulic L, Surucu B, Hynx D, Hemmings BA (2008) PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 30: 203-213. (Pubitemid 351626686)
17. Alexander A, Cai SL, Kim J, Nanez A, Sahin M, et al. (2010) ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci U S A 107: 4153-4158.
18. Kastan MB, Lim DS (2000) The many substrates and functions of ATM. Nat Rev Mol Cell Biol 1: 179-186.
19. Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171-182.
20. Crew KD, Gammon MD, Terry MB, Zhang FF, Zablotska LB, et al. (2007) Polymorphisms in nucleotide excision repair genes, polycyclic aromatic hydrocarbon-DNA adducts, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 16: 2033-2041. (Pubitemid 47621177)
21. Fu YP, Yu JC, Cheng TC, Lou MA, Hsu GC, et al. (2003) Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility. Cancer Res 63: 2440-2446. (Pubitemid 36605181)
22. Kuschel B, Auranen A, McBride S, Novik KL, Antoniou A, et al. (2002) Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 11: 1399-1407.
23. Smith TR, Levine EA, Perrier ND, Miller MS, Freimanis RI, et al. (2003) DNA-repair genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 12: 1200-1204. (Pubitemid 37499444)
24. Wang X, Szabo C, Qian C, Amadio PG, Thibodeau SN, et al. (2008) Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers. Cancer Res 68: 971-975. (Pubitemid 351272213)
25. Concannon P, Haile RW, Borresen-Dale AL, Rosenstein BS, Gatti RA, et al. (2008) Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. Cancer Res 68: 6486-6491.
26. Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, et al. (2008) Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol 2: 296-316.
27. Nagelkerke A, van Kuijk SJ, Sweep FC, Nagtegaal ID, Hoogerbrugge N, et al. (2011) Constitutive expression of gamma-H2AX has prognostic relevance in triple negative breast cancer. Radiother Oncol 101: 39-45.
28. Kim SH, Miller FR, Tait L, Zheng J, Novak RF (2009) Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions: biomarkers of progression. Int J Cancer 124: 2813-2828.
29. Kadota M, Yang HH, Gomez B, Sato M, Clifford RJ, et al. (2010) Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One 5: e9201.
30. So JY, Lee HJ, Kramata P, Minden A, Suh N (2012) Differential expression of key signaling proteins in MCF10 cell lines, a human breast cancer progression model. Molecular and Cellular Pharmacology 4: 31-40.